6/13
08:14 am
sonn
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain [Yahoo! Finance]
Medium
Report
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain [Yahoo! Finance]
6/13
08:00 am
sonn
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
Low
Report
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
5/28
08:24 am
sonn
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting [Yahoo! Finance]
Low
Report
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting [Yahoo! Finance]
5/28
08:00 am
sonn
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock.
Low
Report
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock.
5/28
08:00 am
sonn
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Low
Report
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
5/22
07:22 am
sonn
Sonnet BioTherapeutics Announces Review of Strategic Alternatives [Yahoo! Finance]
Medium
Report
Sonnet BioTherapeutics Announces Review of Strategic Alternatives [Yahoo! Finance]
5/22
07:00 am
sonn
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
Medium
Report
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
5/20
09:26 am
sonn
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target [Yahoo! Finance]
Medium
Report
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target [Yahoo! Finance]
5/20
09:15 am
sonn
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Medium
Report
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
5/14
04:28 pm
sonn
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update [Yahoo! Finance]
Low
Report
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update [Yahoo! Finance]
5/14
04:15 pm
sonn
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Low
Report
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
5/6
07:00 am
sonn
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Low
Report
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
5/3
09:08 am
sonn
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference [Yahoo! Finance]
Medium
Report
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference [Yahoo! Finance]